David Tai
National Cancer Centre Singapore(SG)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Lung Cancer Treatments and Mutations, Cholangiocarcinoma and Gallbladder Cancer Studies
Most-Cited Works
- → Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study(2021)430 cited
- → Liver Biochemical Tests and Dengue Fever(1992)343 cited
- → Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors(2021)337 cited
- → Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO(2020)235 cited
- → Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer(2019)207 cited
- → Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial(2025)177 cited
- → Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study(2019)170 cited
- → Targeting the WNT Signaling Pathway in Cancer Therapeutics(2015)158 cited
- → Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.(2024)143 cited
- → Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond(2020)133 cited